B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating
B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating
由于肥胖症增加+NASH Therapeutics的产品销售预测，B. Riley将Altimmune的PT从15美元上调至20美元；维持买入评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册